Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Date:3/20/2009

boplatin are delivered to patients with escalating intravenous dosages of REOLYSIN(R). Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The second component of the trial is a Phase II, 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists.

An independent, confirmatory Phase II trial using the same combination of REOLYSIN(R) and carboplatin/paclitaxel for patients with head and neck cancers is currently underway in the U.S. Interim results from both the U.K. and the U.S. study formed the basis of the Phase III pivotal program now being developed for REOLYSIN(R) in combination with carboplatin/paclitaxel in this patient population.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Compan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Miami, FL (PRWEB) May 20, 2013 Researchers ... information in the connection between lower back pain, and the ... of P.acnes in the system the bacteria seek out oxygen ... is incurred in the spinal column, P.acnes has the ability ... pain. , Fernando Perez, a spokesman for “ The ...
(Date:5/20/2013)... Recognizing exciting and innovative scientific ... its 2013 Class of Young Professors. Over ... this outstanding international group with more than $824,000 ... to meet global challenges.     , The DuPont Young ... and untenured research faculty working in areas of ...
(Date:5/20/2013)... May 20, 2013 On 25-28 July, ... – in Paris - the beautiful city of lights. ... "Personalized Medicine is revolutionizing the medical world. Understanding and ... is the hallmark of this transformation. Much of the ... from the epidemiologic studies of large cohorts that do ...
(Date:5/20/2013)... Kitware, a leader in data visualization, today ... exploration of hospital costs across the United States ... recent release of “Medicare Provider Charge Data,” a dataset ... from the Centers for Medicare & Medicaid Services. , ... hospitals across the country has sparked considerable controversy; however, ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2Kitware Enables Interactive Exploration of CMS Medicare Data 2
... , , ... today announced that it has been awarded two Phase I ... the National Institute of Allergy and Infectious Diseases (NIAID) of ... be used to perform additional preclinical toxicology and pharmacology studies ...
... , , , ... ), the leading global provider of risk management services, ... human capital consulting , today issued the findings of its 2009 ... biotechnology , pharmaceutical and medical ...
... YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain, ... Sept. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... development company that identifies and advances a diverse portfolio ... today reported that nimotuzumab has been approved for marketing ...
Cached Biology Technology:Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome 2Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 2Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 3Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 4Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 5YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 4
(Date:5/19/2013)... study reports that white men and women of European ... valgus) and lesser toe deformities, including hammer or claw ... estimate the heritability of foot disorders in humansappear in ... by Wiley on behalf of the American College of ... many as 60% of older adults have foot disorders ...
(Date:5/19/2013)... a strain of electricity-producing bacteria that can grow using ... dioxide as its sole source of carbon. Researchers ... at the 113th General Meeting of the American Society ... current production solely on hydrogen," says Amit Kumar, a ... are part of the Lovley Lab Group at the ...
(Date:5/19/2013)... engineered a strain of photosynthetic cyanobacteria to grow without ... today at the 113th General Meeting of the American ... synthetic biology approaches to probe and rewire photoautotrophic (exclusively ... cyanobacterial metabolism for the ability to grow without light ... study. He is part of Shota Atsumi,s lab ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2
... edition of the Oxford English Dictionary boasts 22,000 pages of ... suggests the reference manual is meticulously organized to be as ... our brains make sense of and categorize the countless words ... of as a frustratingly tangled web of words where the ...
... by Yale scientists shows that males and females have essentially ... a recent report in Cell designed to identify factors that ... showed that a courting song and dance routine that only ... wiggled to make a humming song can also be ...
... of Southern California School of Dentistry researchers says it ... some people taking drugs that treat osteoporosis. Microbial ... are causing jaw tissue infections in patients taking bisphosphonate ... professor at the USC School of Dentistry. ...
Cached Biology News:Decoding the dictionary: Study suggests lexicon evolved to fit in the brain 2Decoding the dictionary: Study suggests lexicon evolved to fit in the brain 3It's a unisex brain with specific signals that trigger 'male' behavior 2USC School of Dentistry researchers uncover link between osteoporosis drugs and jaw infection 2
... Attoglow Western Blot Analysis Kit is ... kit developed by Biochain. It detects ... g) or yoctomole (10 -24 ... three parts: Millennium Enhancer, protein interaction ...
Request Info...
Cultrex 3D Culture Matrix Rat Collagen I....
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
Biology Products: